Keybank National Association OH cut its stake in Haemonetics Corporation (NYSE:HAE) by 23.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,975 shares of the medical instruments supplier’s stock after selling 12,225 shares during the period. Keybank National Association OH owned about 0.07% of Haemonetics Corporation worth $1,539,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HAE. Shine Investment Advisory Services Inc. purchased a new stake in shares of Haemonetics Corporation during the second quarter valued at approximately $132,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Haemonetics Corporation during the first quarter valued at approximately $179,000. State of Alaska Department of Revenue raised its stake in shares of Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares during the last quarter. AXA purchased a new stake in shares of Haemonetics Corporation during the first quarter valued at approximately $292,000. Finally, Eqis Capital Management Inc. purchased a new stake in shares of Haemonetics Corporation during the second quarter valued at approximately $305,000.

Shares of Haemonetics Corporation (NYSE HAE) opened at 43.61 on Friday. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.74. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 566.36 and a beta of 0.88. The firm’s 50-day moving average price is $41.37 and its 200 day moving average price is $40.50.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The business had revenue of $211 million during the quarter, compared to analyst estimates of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The company’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business posted $0.25 EPS. On average, analysts predict that Haemonetics Corporation will post $1.60 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/03/haemonetics-corporation-hae-shares-sold-by-keybank-national-association-oh.html.

Several analysts recently commented on the company. Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Wednesday, August 9th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. BidaskClub raised Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Tuesday, August 8th. Finally, JMP Securities raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $40.71.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.